299 assets in Lung Cancer

Therapeutic assets addressing Lung Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Lung Cancer	SystImmune Inc.	P4	BB (70)
Cis-Diamminedichloroplatinum Ii Lung Cancer	University of Vermont	P4	BB (70)
Etoposide Lung Cancer	SystImmune Inc.	P3	BB (69)
Nivolumab Lung Cancer	University of Chicago	P4	BB (69)
Propofol Lung Cancer	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	BB (69)
Docetaxel Lung Cancer	SWOG Cancer Research Network	P3	BB (68)
Irinotecan Lung Cancer	City of Hope Medical Center	P3	BB (68)
Sevoflurane Lung Cancer	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	BB (68)
Vinorelbine Ditartrate Lung Cancer	Alliance for Clinical Trials in Oncology	P3	BB (68)
Gefitinib Lung Cancer	Fuzhou General Hospital	P3	BB (67)
Cyclophosphamide Lung Cancer	City of Hope Medical Center	P3	BB (66)
Nogitecan Lung Cancer	Fox Chase Cancer Center	P3	BB (66)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Lung Cancer	University of Chicago	P2/3	BB (65)
Ipilimumab Lung Cancer	University of Chicago	P4	BB (65)
Oxaliplatin Lung Cancer	Tango Therapeutics, Inc.	P2/3	BB (65)
Recombinant Human Egf-Rp64K Lung Cancer	Roswell Park Cancer Institute	P2	BB (65)
Adagrasib Lung Cancer	Roswell Park Cancer Institute	P2	BB (64)
Dexasone Lung Cancer	SWOG Cancer Research Network	P4	BB (64)
Epirubicin Lung Cancer	City of Hope Medical Center	P3	BB (64)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Lung Cancer	University of Chicago	P3	BB (64)
Nicotine Lung Cancer	Ohio State University Comprehensive Cancer Center	P4	BB (64)
Sotorasib Lung Cancer	National Cancer Institute (NCI)	P2	BB (64)
Atezolizumab Lung Cancer	University of Washington	P4	B (63)
Catequentinib Lung Cancer	Shanghai Chest Hospital	P3	B (63)
Montanide Isa 51 Lung Cancer	Roswell Park Cancer Institute	P2	B (63)
Osimertinib Lung Cancer	Beijing Pearl Biotechnology Limited Liability Company	P3	B (63)
Prednisone Lung Cancer	Pfizer	P4	B (63)
Sargramostim Lung Cancer	University of Washington	P2	B (63)
Tislelizumab Lung Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (63)
Cediranib Lung Cancer	City of Hope Medical Center	P3	B (62)
Cetuximab Lung Cancer	Merck Sharp & Dohme LLC	P3	B (62)
Crizotinib Lung Cancer	Sun Yat-sen University	P3	B (62)
Nivestim Lung Cancer	University of Washington	P3	B (62)
Panitumumab Lung Cancer	Institut de Recherches Internationales Servier	P2	B (62)
Pembrolizumab Lung Cancer	City of Hope Medical Center	P3	B (62)
Thalidomide Lung Cancer	Tongji University	P4	B (62)
Alectinib Lung Cancer	Joshua Palmer	P4	B (61)
Trastuzumab Lung Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	B (61)
Ceralasertib Lung Cancer	National Cancer Institute (NCI)	P3	B (60)
Durvalumab Lung Cancer	University of Chicago	P3	B (60)
Famitinib Lung Cancer	Hansoh BioMedical R&D Company	P3	B (60)
Fluorouracilum Lung Cancer	Tango Therapeutics, Inc.	P2/3	B (60)
Icotinib Lung Cancer	Fuzhou General Hospital	P3	B (60)
Lurbinectedin Lung Cancer	SystImmune Inc.	P3	B (60)
Trametinib Lung Cancer	Sun Yat-sen University	P2	B (60)
Avutometinib Lung Cancer	Emory University	P2	B (59)
Disitamab Vedotin Lung Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (59)
Fludarabine Lung Cancer	Pfizer	P3	B (58)
Fludeoxyglucose Lung Cancer	Peking University Cancer Hospital & Institute	P3	B (58)
Infliximab Lung Cancer	M.D. Anderson Cancer Center	P3	B (58)

Showing 1 to 50 of 299 assets

PreviousPage 1 of 6Next